Clinical Trial Update: PALACE: Cemiplimab Trial According to ctDNA Levels [Phase 2]

View source ↗

Summary

Phase 2 PALACE trial assesses cemiplimab guided by circulating ctDNA levels in non-small cell lung cancer and related thoracic neoplasms; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cemiplimab (Libtayo) (cemiplimab)

Snippet

Sponsor: Fundación GECP | Conditions: Non Small Cell Lung Cancer Metastatic, Lung Diseases | Phase 2 | Status: RECRUITING